AU2006325658B2 - Solid dispersion comprising an active ingredient having a low melting point and tablet for oral administration comprising same - Google Patents

Solid dispersion comprising an active ingredient having a low melting point and tablet for oral administration comprising same Download PDF

Info

Publication number
AU2006325658B2
AU2006325658B2 AU2006325658A AU2006325658A AU2006325658B2 AU 2006325658 B2 AU2006325658 B2 AU 2006325658B2 AU 2006325658 A AU2006325658 A AU 2006325658A AU 2006325658 A AU2006325658 A AU 2006325658A AU 2006325658 B2 AU2006325658 B2 AU 2006325658B2
Authority
AU
Australia
Prior art keywords
tablet
solid dispersion
pharmaceutically acceptable
fused solid
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006325658A
Other languages
English (en)
Other versions
AU2006325658A1 (en
Inventor
Sang Wook Kim
Jae Kuk Ryu
Jong Soo Woo
Hong Gi Yi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanmi Science Co Ltd
Original Assignee
Hanmi Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Science Co Ltd filed Critical Hanmi Science Co Ltd
Publication of AU2006325658A1 publication Critical patent/AU2006325658A1/en
Application granted granted Critical
Publication of AU2006325658B2 publication Critical patent/AU2006325658B2/en
Assigned to HANMI HOLDINGS CO., LTD. reassignment HANMI HOLDINGS CO., LTD. Request for Assignment Assignors: HANMI PHARM. CO., LTD.
Assigned to HANMI SCIENCE CO., LTD. reassignment HANMI SCIENCE CO., LTD. Request to Amend Deed and Register Assignors: HANMI HOLDINGS CO., LTD.
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2006325658A 2005-12-16 2006-12-18 Solid dispersion comprising an active ingredient having a low melting point and tablet for oral administration comprising same Ceased AU2006325658B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2005-0124386 2005-12-16
KR20050124386 2005-12-16
PCT/KR2006/005526 WO2007069874A1 (en) 2005-12-16 2006-12-18 Solid dispersion comprising an active ingredient having a low melting point and tablet for oral administration comprising same

Publications (2)

Publication Number Publication Date
AU2006325658A1 AU2006325658A1 (en) 2007-06-21
AU2006325658B2 true AU2006325658B2 (en) 2010-04-08

Family

ID=38163142

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006325658A Ceased AU2006325658B2 (en) 2005-12-16 2006-12-18 Solid dispersion comprising an active ingredient having a low melting point and tablet for oral administration comprising same

Country Status (14)

Country Link
US (1) US20080292702A1 (enExample)
EP (1) EP1968542B1 (enExample)
JP (1) JP2009519326A (enExample)
CN (1) CN101330904B (enExample)
AU (1) AU2006325658B2 (enExample)
BR (1) BRPI0619868A8 (enExample)
CA (1) CA2633266C (enExample)
ES (1) ES2429097T3 (enExample)
IL (1) IL191804A0 (enExample)
NO (1) NO339674B1 (enExample)
NZ (1) NZ569813A (enExample)
RU (1) RU2403013C2 (enExample)
WO (1) WO2007069874A1 (enExample)
ZA (1) ZA200806138B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06002731A (es) 2003-09-11 2006-06-05 Xenoport Inc Tratamiento y/o prevencion de incontinencia urinaria utilizando profarmacos de analogos de gaba.
KR101005391B1 (ko) * 2008-07-22 2010-12-30 한국콜마 주식회사 덱시부프로펜 함유 서방출성 시럽제 및 그의 제조방법
KR101067224B1 (ko) * 2008-07-22 2011-09-22 한국콜마 주식회사 이부프로펜 함유 서방출성 시럽제 및 그의 제조방법
CN101961306B (zh) * 2009-07-24 2011-11-09 北京化工大学 一种低熔点药物固体分散体的制备方法
CN102144982B (zh) * 2011-03-30 2012-12-12 江苏神龙药业有限公司 一种米诺膦酸片及其制备方法
CN102406940B (zh) * 2011-11-01 2013-07-03 温州大学 一种纳米级片状羧甲基淀粉钠在固体分散体中的应用
WO2013154511A1 (en) * 2012-04-13 2013-10-17 Mahmut Bilgic Film tablet formulations comprising dexibuprofen
UY36046A (es) 2014-03-26 2015-10-30 Millennium Pharm Inc Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
JP6647902B2 (ja) * 2015-10-30 2020-02-14 株式会社ファンケル 徐放性顆粒剤
CN106265522A (zh) * 2016-08-30 2017-01-04 铜陵翔宇商贸有限公司 布洛芬‑pvp共沉淀物及其制备方法
JP7147262B2 (ja) * 2017-05-23 2022-10-05 大正製薬株式会社 固形製剤
JP7109255B2 (ja) * 2017-05-23 2022-07-29 ライオン株式会社 粉砕物の製造方法及び錠剤の製造方法
EP3658123A4 (en) * 2017-07-24 2021-04-28 Acryspharm LLC PHARMACEUTICAL COMPOSITIONS WITH A HIGH DRUG LOAD
RU2685294C1 (ru) * 2018-05-10 2019-04-17 Общество с ограниченной ответственностью "ДИНОН" (ООО "ДИНОН") Поглотитель, способ его приготовления (варианты) и способ удаления диоксида углерода из газовых смесей
CN112263567B (zh) * 2020-10-19 2022-05-03 南京易亨制药有限公司 一种布洛芬缓释胶囊及制备方法
CN117363320B (zh) * 2023-12-07 2024-02-13 黑龙江省鑫博鑫交通科技有限公司 一种公路用融雪剂及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001041733A2 (en) * 1999-12-09 2001-06-14 The Boots Company Plc Compressed tablet composition comprising a nsaid

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56120616A (en) * 1980-02-27 1981-09-22 Kaken Pharmaceut Co Ltd Ibuprofen-containing granule, its preparation, and internal medicine comprising it
GB8601204D0 (en) * 1986-01-18 1986-02-19 Boots Co Plc Therapeutic agents
CH669523A5 (enExample) * 1986-06-25 1989-03-31 Mepha Ag
US4806359A (en) * 1987-04-22 1989-02-21 Mcneilab, Inc. Iburprofen sustained release matrix and process
DE19509807A1 (de) * 1995-03-21 1996-09-26 Basf Ag Verfahren zur Herstellung von Wirkstoffzubereitungen in Form einer festen Lösung des Wirkstoffs in einer Polymermatrix sowie mit diesem Verfahren hergestellte Wirkstoffzubereitungen
IE80467B1 (en) * 1995-07-03 1998-07-29 Elan Corp Plc Controlled release formulations for poorly soluble drugs
US6391338B1 (en) * 1995-09-07 2002-05-21 Biovail Technologies Ltd. System for rendering substantially non-dissoluble bio-affecting agents bio-available
DE19536394A1 (de) * 1995-09-29 1997-04-03 Basf Ag Feste Arzneiformen, erhältlich durch Extrusion einer Isomalt enthaltenden Polymer-Wirkstoff-Schmelze
DE69739165D1 (de) * 1996-07-08 2009-01-29 Penwest Pharmaceuticals Co Matrix mit verzögerter freisetzung für hochdosierte unlösliche arzneistoffe
US6787157B1 (en) * 1998-03-10 2004-09-07 Abbott Laboratories Multiphase active ingredient-containing formulations
US6183779B1 (en) * 1999-03-22 2001-02-06 Pharmascience Inc. Stabilized pharmaceutical composition of a nonsteroidal anti-inflammatory agent and a prostaglandin
GB0113839D0 (en) * 2001-06-07 2001-08-01 Boots Co Plc Therapeutic agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001041733A2 (en) * 1999-12-09 2001-06-14 The Boots Company Plc Compressed tablet composition comprising a nsaid

Also Published As

Publication number Publication date
AU2006325658A1 (en) 2007-06-21
EP1968542A4 (en) 2010-06-02
CA2633266C (en) 2011-08-02
IL191804A0 (en) 2008-12-29
JP2009519326A (ja) 2009-05-14
HK1126671A1 (en) 2009-09-11
NO339674B1 (no) 2017-01-23
RU2403013C2 (ru) 2010-11-10
BRPI0619868A2 (pt) 2011-10-25
ZA200806138B (en) 2009-11-25
CA2633266A1 (en) 2007-06-21
BRPI0619868A8 (pt) 2016-06-07
ES2429097T3 (es) 2013-11-13
NZ569813A (en) 2011-07-29
CN101330904B (zh) 2012-04-18
RU2008129041A (ru) 2010-01-27
EP1968542A1 (en) 2008-09-17
EP1968542B1 (en) 2013-08-14
NO20083151L (no) 2008-09-05
WO2007069874A1 (en) 2007-06-21
US20080292702A1 (en) 2008-11-27
CN101330904A (zh) 2008-12-24

Similar Documents

Publication Publication Date Title
AU2006325658B2 (en) Solid dispersion comprising an active ingredient having a low melting point and tablet for oral administration comprising same
JP5632367B2 (ja) Ｂｉｂｗ２９９２を含有する固形医薬製剤
JP6404217B2 (ja) エンザルタミドの製剤
NO314124B1 (no) Fremgangsmåte for fremstilling av partikler
JPH02104A (ja) 薬物放出速度調節型製剤
TW201711687A (zh) 帕博西里之固態劑型
CN114177157B (zh) 含有药物的立即释放片剂和用于形成片剂的方法
KR20100063090A (ko) 알리스키렌 및 발사르탄의 생약 제제
CN106265580A (zh) Somcl-9112固体分散体、其制备方法及包含其的somcl-9112固体制剂
US20130102682A1 (en) Fingolimod in the form of a solid solution
Mankala et al. Preparation and characterization of mucoadhesive microcapsules of gliclazide with natural gums
CN102164584A (zh) 包含阿利吉仑的盖仑制剂及通过熔融挤出制粒的其制备方法
Panainte et al. New modified release tablets of bisoprolol fumarate for the treatment of hypertension: characterization and in vitro evaluation
KR20000069356A (ko) 급속방출식 약물전달 제형
MX2008007665A (en) Solid dispersion comprising an active ingredient having a low melting point and tablet for oral administration comprising same
CN112972396A (zh) 一种非布司他控释组合物及其制备方法
HK1126671B (en) Solid dispersion comprising an active ingredient having a low melting point and tablet for oral administration comprising same
CN120676932A (zh) 贝祖拉替尼制剂
KR20240025595A (ko) 고형제의 멜라토닌 제제
TWI353836B (en) Process for producing pharmaceutical preparation c
CN116893086A (zh) 一种靶向药甲磺酸伏美替尼片的模拟片及其制备方法
Shirazi Hot melt extrusion for solid dispersion of BCS Class II drugs: An approach to replace conventional polymers with sugars
HK1065952B (en) Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it
HK1065952A1 (en) Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: HANMI HOLDINGS CO., LTD.

Free format text: FORMER OWNER WAS: HANMI PHARM. CO., LTD.

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE PATENTEE TO READ HANMI SCIENCE CO., LTD. .

MK14 Patent ceased section 143(a) (annual fees not paid) or expired